Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 237

1.

Nasally inhaled dornase alfa in the postoperative management of chronic sinusitis due to cystic fibrosis.

Raynor EM, Butler A, Guill M, Bent JP 3rd.

Arch Otolaryngol Head Neck Surg. 2000 May;126(5):581-3.

PMID:
10807324
2.

Dornase alfa as postoperative therapy in cystic fibrosis sinonasal disease.

Cimmino M, Nardone M, Cavaliere M, Plantulli A, Sepe A, Esposito V, Mazzarella G, Raia V.

Arch Otolaryngol Head Neck Surg. 2005 Dec;131(12):1097-101.

PMID:
16365224
3.

A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities.

Quan JM, Tiddens HA, Sy JP, McKenzie SG, Montgomery MD, Robinson PJ, Wohl ME, Konstan MW; Pulmozyme Early Intervention Trial Study Group..

J Pediatr. 2001 Dec;139(6):813-20.

PMID:
11743506
4.

A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis.

Fitzgerald DA, Hilton J, Jepson B, Smith L.

Pediatrics. 2005 Oct;116(4):e549-54. Epub 2005 Sep 1.

PMID:
16147970
5.

Effect of smaller droplet size of dornase alfa on lung function in mild cystic fibrosis. Dornase Alfa Nebulizer Group.

Geller DE, Eigen H, Fiel SB, Clark A, Lamarre AP, Johnson CA, Konstan MW.

Pediatr Pulmonol. 1998 Feb;25(2):83-7.

PMID:
9516090
6.

Does the timing of inhaled dornase alfa matter?

van der Giessen L.

J Cyst Fibros. 2009 Jun;8 Suppl 1:S6-9. doi: 10.1016/S1569-1993(09)60004-7.

8.

Sinonasal inhalation of dornase alfa in CF: A double-blind placebo-controlled cross-over pilot trial.

Mainz JG, Schiller I, Ritschel C, Mentzel HJ, Riethm├╝ller J, Koitschev A, Schneider G, Beck JF, Wiedemann B.

Auris Nasus Larynx. 2011 Apr;38(2):220-7. doi: 10.1016/j.anl.2010.09.001. Epub 2010 Oct 27.

PMID:
21030168
9.

Nebulised dornase alpha: adherence in adults with cystic fibrosis.

Burrows JA, Bunting JP, Masel PJ, Bell SC.

J Cyst Fibros. 2002 Dec;1(4):255-9.

10.
11.

Dornase alfa. A review of pharmacoeconomic and quality-of-life aspects of its use in cystic fibrosis.

Goa KL, Lamb H.

Pharmacoeconomics. 1997 Sep;12(3):409-22. Review.

PMID:
10170464
12.

[Respiratory evolution of patient with mucoviscidosis treated with mucolytic agents plus dornase alfa].

Derelle J, Bertolo-Houriez E, Marchal F, Weber M, Virion JM, Vidailhet M.

Arch Pediatr. 1998 Apr;5(4):371-7. French.

PMID:
9759155
13.
14.
15.

Dornase alfa: a new option in the management of cystic fibrosis.

Witt DM, Anderson L.

Pharmacotherapy. 1996 Jan-Feb;16(1):40-8. Review.

PMID:
8700791
16.

Medical management of chronic rhinosinusitis in cystic fibrosis: a systematic review.

Liang J, Higgins T, Ishman SL, Boss EF, Benke JR, Lin SY.

Laryngoscope. 2014 Jun;124(6):1308-13. doi: 10.1002/lary.24503. Epub 2013 Dec 11. Review.

PMID:
24338982
17.

Dornase alfa is well tolerated: data from the epidemiologic registry of cystic fibrosis.

McKenzie SG, Chowdhury S, Strandvik B, Hodson ME; Investigators of the Epidemiologic Registry of Cystic Fibrosis..

Pediatr Pulmonol. 2007 Oct;42(10):928-37.

PMID:
17726701
18.
19.

Small airway deposition of dornase alfa during exacerbations in cystic fibrosis; a randomized controlled clinical trial.

Bakker EM, Volpi S, Salonini E, M├╝llinger B, Kroneberg P, Bakker M, Hop WC, Assael BM, Tiddens HA.

Pediatr Pulmonol. 2014 Feb;49(2):154-61. doi: 10.1002/ppul.22800. Epub 2013 Jul 3.

PMID:
23913868
20.

Triological thesis: concurrent endoscopic sinus surgery and cosmetic rhinoplasty: rationale, risks, rewards, and reality.

Sclafani AP, Schaefer SD.

Laryngoscope. 2009 Apr;119(4):778-91. doi: 10.1002/lary.20098.

PMID:
19160399

Supplemental Content

Support Center